Clinical Trial Update: A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the combined impact of Omega-3 carboxylic acids and dapagliflozin on liver fat content in patients with type 2 diabetes and non-alcoholi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• Omega-3 carboxylic acids

Snippet

Sponsor: AstraZeneca | Conditions: T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin) | Phase 2 | Status: COMPLETED | Results posted: 2017-01-27